VolitionRx (NYSE: VNRX)

Last close As at 13/12/2024

USD0.61

−0.04 (−6.30%)

Market capitalisation

USD61m

VolitionRx is a clinical diagnostics company developing easy-to-use and cost-effective blood tests to diagnose a range of diseases in humans and animals including sepsis and cancer. Diagnostic Nu.Q tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid.

Latest Insights

View More

Healthcare | edison tv

Volition webinar: Nu.Q NETs data insights

Healthcare | Update

VolitionRx — Snaring sepsis, with early NETs detection

Sector

Healthcare

Equity Analyst

Jyoti Prakash

Jyoti Prakash

Analyst, Healthcare

Arron Aatkar

Analyst

Key Management

  • Cameron Reynolds

    CEO

  • Jake Micallef

    Chief Scientific Officer

  • Scott Powell

    Director of IR

  • Terig Hughes

    CFO

Further insights

insight

Healthcare

Volition: Views from the sharp end

insight

Healthcare

Healthcare Week 2023

Thematics

volition01

thematic

Healthcare

VolitionRx – Decoding the DNA of cancer 

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free